Literature DB >> 8288677

The relevance of flow-cytometric DNA content in the evaluation of lung cancer.

F Salvati1, L Teodori, M L Trinca, R Pasquali-Lasagni, W Göhde.   

Abstract

Cells from a group of 185 patients suffering from malignant tumours (160 non-small-cell lung carcinoma, 13 small-cell lung carcinoma, and 12 non-epithelial tumours) and 6 with benign lung tumours were studied by flow cytometry in order to detect the prognostic value of DNA content. A total of 144 (90%) non-small-cell lung carcinomas (NSCLC) and 8 (62%) small-cell lung carcinomas (SCLC) exhibited aneuploidy. Furthermore 52% (83 patients) NSCLC, 24% (3 patients) SCLC and 50% (6 patients) non-epithelial tumours demonstrated multiclonality. Benign cases showed diploid DNA content. For actuarial survival analysis using the Bergesson and Gage method and the Greenwood variance, 142 patients were selected. Statistical comparisons were made by the use of the t-test for unpaired data between fixed times. No correlation was observed between ploidy and stage, histological grading or treatment modality. A statistically significantly better survival was observed after 12, 18 and 24 months of follow-up for diploid and monoclonal (with the exclusion of hypo- and hypertetraploid) patients. Thus, flow-cytometric DNA analysis may be useful in prognostic assessment of human lung tumours.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8288677     DOI: 10.1007/BF01372562

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  29 in total

1.  Calculation of survival rates for cancer.

Authors:  J BERKSON; R P GAGE
Journal:  Proc Staff Meet Mayo Clin       Date:  1950-05-24

Review 2.  Flow cytometry in clinical cancer research.

Authors:  B Barlogie; M N Raber; J Schumann; T S Johnson; B Drewinko; D E Swartzendruber; W Göhde; M Andreeff; E J Freireich
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

3.  Combined modality therapy of cancer. What is it and when does it work?

Authors:  S A Rosenberg
Journal:  N Engl J Med       Date:  1985-06-06       Impact factor: 91.245

4.  Flow cytometric analysis of the DNA content of non-small cell lung cancer. Ploidy as a significant prognostic indicator in squamous cell carcinoma of the lung.

Authors:  A A Sahin; J Y Ro; A K el-Naggar; J S Lee; A G Ayala; K Teague; W K Hong
Journal:  Cancer       Date:  1990-02-01       Impact factor: 6.860

5.  Phenotypic heterogeneity studied by immunohistochemistry and aneuploidy in non-small cell lung cancers.

Authors:  J L Pujol; J Simony; J C Laurent; G Richer; H Mary; J Bousquet; P Godard; F B Michel
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

6.  DNA flow cytometric studies of 66 human lung tumors analyzed before treatment. Prognostic implications.

Authors:  F Salvati; L Teodori; L Gagliardi; M Signora; M Aquilini; G Storniello
Journal:  Chest       Date:  1989-11       Impact factor: 9.410

7.  Prognostic significance of flow cytometry in lung cancer. A 5-year study.

Authors:  D Tirindelli-Danesi; L Teodori; F Mauro; C Modini; C Botti; F Cicconetti; S Stipa
Journal:  Cancer       Date:  1987-08-15       Impact factor: 6.860

8.  Flow cytometry as a tool for the prognostic assessment of human neoplasia.

Authors:  F Mauro; L Teodori; J Schumann; W Göhde
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-04       Impact factor: 7.038

9.  DNA content in correlation with postsurgical stage in non-small cell lung cancer.

Authors:  N Z Carp; D D Ellison; P F Brophy; P Watts; M C Chang; S M Keller
Journal:  Ann Thorac Surg       Date:  1992-04       Impact factor: 4.330

10.  DNA cytofluorometric and nuclear morphometric analyses of lung adenocarcinoma.

Authors:  H Asamura; T Nakajima; K Mukai; M Noguchi; Y Shimosato
Journal:  Cancer       Date:  1989-10-15       Impact factor: 6.860

View more
  4 in total

1.  Selection, establishment and characterization of cell lines derived from a chemically-induced rat mammary heterogeneous tumor, by flow cytometry, transmission electron microscopy, and immunohistochemistry.

Authors:  L Teodori; F Tagliaferri; F Stipa; M G Valente; D Coletti; A Manganelli; M Guglielmi; L S D'Angelo; H Schäfer; W Göhde
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-03       Impact factor: 2.416

2.  Flow cytometric analysis of tumor DNA profile related to response to treatment and survival in small-cell lung cancer.

Authors:  M M Virén; A T Ojala; V V Kataja; J J Mattila; P A Koivisto; V T Nikkanen
Journal:  Med Oncol       Date:  1997-03       Impact factor: 3.064

3.  Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data.

Authors:  D Choma; J P Daurès; X Quantin; J L Pujol
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

4.  Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer.

Authors:  K Nakagawa; H Tada; A Akashi; T Yasumitsu; K Iuchi; T Taki; K Kodama
Journal:  Br J Cancer       Date:  2006-09-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.